Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Diabetes and Rheumatoid Arthritis: A Missing Link?

Diabetes and Rheumatoid Arthritis: A Missing Link?

  • November 2, 2017
  • Posted in Disease Awareness

This post was last updated on October 26, 2020 at 3:24 pm

Is there an unidentified link between diabetes and RA?

By Jason Bhan, MD, Fernando Schwartz, PhD, and Lauren Wiener

Diabetes and rheumatoid arthritis (RA) are certainly two of the most common and well-known diseases faced by the US population today.  While it may seem that we know plenty about these two conditions, recently Prognos set out to discover more.  Although diabetes and RA may not seem very similar, they do share the physiological link of causing an inflammatory response, and we wondered if they might share even more.

Could there be a link between diabetes and RA?  Smaller research papers have conducted investigations to suggest they could be a comorbidity between the two conditions, but this is not mentioned in the current standard of care.  Follow along in our latest blog series to learn if our research suggests the same.

Background

Diabetes is a disease in which the body’s ability to produce or respond to insulin is impaired, leading to higher levels of glucose in the blood. Currently, 6.5% of the population suffers from type 2 diabetes.  Diabetes is indicative of poor health in general, and is associated with obesity, poor cardiovascular health, and many other conditions.  Systemic inflammation may be associated with diabetes, which may also account for inflammatory comorbid conditions.

Rheumatoid arthritis is an autoinflammatory disease in which the body produces antibodies that causes the body to attack itself. This inflammation affects a patient’s joints, causing stiffness, swelling, and pain. The underlying inflammation that RA causes can also affect other parts of the body, such as the skin, lungs, and cardiovascular system.

Both diabetes and RA are systemic inflammatory diseases.  Given this shared inflammatory physiology, a comorbidity between these two diseases could be expected.  A study with a sample size of 340 RA patients found that 31% had diabetes, and a similar study of 17,887 RA patients found a comorbidity with diabetes in 12.9% of RA patients. Despite these findings, current standard of care guidelines for diabetes and RA do not account for this comorbidity. Rheumatoid arthritis and diabetes patients can benefit from prevention and early intervention, so this overlooked comorbidity may be indicative of a missed opportunity to improve outcomes.

Hypothesis and Associated Risks

We believe that our analysis will point to a comorbidity between diabetes and RA, and we hope to demonstrate this comorbidity on a larger scale. Furthermore, we will investigate if RA patients with a double positive diagnosis will be affected by the presence of a diabetes comorbidity. A double positive diagnosis is defined as RF+ and anti-CCP+, which are both measures of autoantibody levels in rheumatoid arthritis.

Study Design

To determine the comorbidity of diabetes and RA, we will search through our expansive database, The Prognos Registry, and diagnose patients with diabetes, RA, and with a double positive diagnosis of RA. We will calculate the prevalence of diabetes and RA, as well as the percentage of RA patients who have diabetes. This last statistic can be compared to the smaller studies that have reported high levels of comorbidity. We will also find the occurrence of double positive RA diagnosis in comorbid patients as compared to patients with only RA, and perform a chi square test to determine if there is a statistically significant difference between the two populations.

What’s to Come…

Our team looks forward to sharing the findings of our investigation with our readers over the next few weeks.  Follow along with us to read what we’ve found, and feel free to reach out to us with questions or to request additional information.

Reading List

  • http://diabetes.diabetesjournals.org/content/52/7/1799
  • http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388
  • https://professional.diabetes.org/sites/professional.diabetes.org/files/media/dc_40_s1_final.pdf
  • https://www.cdc.gov/arthritis/data_statistics/comorbidities.htm
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623601/
  • http://ard.bmj.com/content/69/7/1292
  • http://onlinelibrary.wiley.com/doi/10.1002/art.11223/full
  • http://onlinelibrary.wiley.com/doi/10.1002/1529-0131(200001)43:1%3C155::AID-ANR20%3E3.0.CO;2-3/full
  • http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176260
  • https://www.ncbi.nlm.nih.gov/pubmed/20851020

Disclosure: Study funded by Prognos, New York, NY.

« 5 Ways Life Science Brands Are Putting AI to Work
Comorbidity Between Diabetes and RA »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.